Device Trial Radar · NCT07327528
Multicentric Pilot Study for the Application of an Endourethral Device for the Treatment of Stress Urinary Incontinence
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 9, 2025
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Relief srlNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 21 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Stress urinary incontinence is defined as the involuntary loss of urine during exertion or physical activity (i.e., sports) or during sneezing or coughing. Approximately 127 million women and 10 million men reported suffering from stress urinary incontinence in 2008, and current estimates are on the rise. The prevalence of stress urinary incontinence is higher in older age groups, with 10% of women and 5% of men over the age of 65 suffering from this condition. The initial management of urinary incontinence consists of basic diagnostic investigations to rule out any reversible conditions (i.e., bacterial urinary tract infections, UTIs), while conservative and non-invasive treatment options include lifestyle changes, (PFMT) with or without biofeedback, and bladder retraining.
Conditions
- Urinary Incontinence , Stress
Interventions
UroRelief, a sterile, single-use, endourethral medical device suitable for both men and women, which is positioned at the bladder neck for the treatment of stress incontinence.Device
UroRelief is a sterile, single-use, endourethral medical device suitable for both men and women, which is positioned at the bladder neck for the treatment of stress incontinence. The device is designed to be inserted through the urethra using a routine endoscopic procedure with a resectoscope. Once in place, the device is completely inside the body with no visible parts outside and can restore urinary continence control.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety of UroReliefTime frame: 18 months
- The safety of UroReliefTime frame: 18 months
- The safety of UroReliefTime frame: 18 months
1 more outcomes with a free account
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy · Recruiting
Azienda Ospedaliero-Universitaria Senese - Policlinico Santa Maria alle Scotte
Siena, Italy · Recruiting
Azienda Ospedaliera Santa Maria di Terni
Terni, Italy · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.